[Prevention of postoperative hyperalgesia].

Abstract

Three types of hyperalgesia can occur during the postoperative period: primary hyperalgesia, which disappears with wound healing, secondary or central hyperalgesia, which can lead to chronic pain, and opiate-induced hyperalgesia. Different drugs, most of which are NMDA receptors antagonists, are used to decrease or prevent the risk of central or opiate-induced hyperalgesia. However, it is difficult to determine whether they are really effective and at which dosage: the results of most published studies are difficult to interpret because of methodological problems. The two most frequent of those are: absence of objective measurement of secondary hyperalgesia and difficulties targeting an at risk population.

• Authors: C Mamie
• Journal: Annales francaises d'anesthesie et de reanimation (Ann Fr Anesth Reanim) Vol. 31 Issue 1 Pg. e39-42 (Jan 2012) ISSN: 1769-6623 [Electronic] France
• Vernacular Title: Prévention de l'hyperalgésie en postopératoire.
• PMID: 22177778 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2011 Société française d’anesthésie et de réanimation (Sfar). Published by Elsevier SAS. All rights reserved.

Chemical References

• Amines
• Analgesics, Non-Narcotic
• Analgesics, Opioid
• Cyclohexanecarboxylic Acids
• Excitatory Amino Acid Antagonists
• Magnesium Compounds
• Receptors, N-Methyl-D-Aspartate
• gamma-Aminobutyric Acid
• Ketamine
• Gabapentin
• Amantadine

Topics

• Amantadine (therapeutic use)
• Amines (therapeutic use)
• Analgesics, Non-Narcotic (therapeutic use)
• Analgesics, Opioid (adverse effects, therapeutic use)
• Cyclohexanecarboxylic Acids (therapeutic use)
• Excitatory Amino Acid Antagonists (therapeutic use)
• Gabapentin
• Humans
• Hyperalgesia (chemically induced, etiology, prevention & control)
• Ketamine (therapeutic use)
• Magnesium Compounds (therapeutic use)
• Pain Management (methods)
• Pain, Postoperative (chemically induced, prevention & control)
• Receptors, N-Methyl-D-Aspartate (antagonists & inhibitors)
• Risk Assessment
• gamma-Aminobutyric Acid (therapeutic use)